M. Germinaro

发表

Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma

E. Bateman, R. Djukanović, M. Castro, 2019, American journal of respiratory and critical care medicine.

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

E. Bateman, S. Korn, P. Bardin, 2019, The journal of allergy and clinical immunology. In practice.

IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy

W. Braun, A. Burks, M. Kulis, 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.

D. Rubin, B. Sands, J. Andrews, 2022, Gastroenterology.

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.

G. Brusselle, J. Zangrilli, M. Germinaro, 2017, Pulmonary pharmacology & therapeutics.

Association of B-cell activating factor receptor deficiency with the P21R polymorphism and common variable immunodeficiency.

M. Germinaro, R. Alam, P. Reynolds, 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

J. Panés, J. Johanns, M. Germinaro, 2022, Journal of Crohn's and Colitis.

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

B. Sands, W. Sandborn, B. Feagan, 2023, The lancet. Gastroenterology & hepatology.

P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease

K. Ngo, A. Stojmirović, J. Perrigoue, 2022, Journal of Crohn's and Colitis.

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.

J. Panés, B. Bressler, J. Johanns, 2022, Gastroenterology & hepatology.

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

C. Lemière, L. Bjermer, J. Maspero, 2016, Chest.

S717 The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy

B. Sands, R. Wilson, J. Panés, 2022, Gastroenterology & hepatology.